[Fibrinolytic treatment of cerebral intraventricular hemorrhage].
BACKGROUND
Spontaneous cerebral intraventricular hemorrhage (SCIVH) is associated with hydrocephaly which requires ventricular drainage as treatment. Maintenance of adequate debit through the drainage system contributes to reduce morbid mortality. When the drain becomes obstructed, intermittent irrigation is necessary. This causes increased intracranial pressure and risk of infection. We propose the use of recombinant plasminogen tissue activator (r-tPA) in the treatment of SCIVH and associated hydrocephaly.


METHODS
We gave two patients with SCIVH 4 cc/day of r-tPA intraventricularly, at a concentration of 1 mg/ml over 4 consecutive days. Daily computerized tomography (CT) series were done. In both cases there was complete resolution of the SCIVH, with no complications related to the treatment. The ventricular drainage systems maintained a constant debit, did not become obstructed and required no revision. The patients did not subsequently require permanent ventricular shunts. One patient died of an unrelated septic condition. The other patient, a year later, could walk unaided, had motor dysphasia and on CT had neither intraventricular blood nor hydrocephaly.


CONCLUSIONS
The intraventricular administration of r-tPA is a valid therapeutic tool in selected cases. It contributes to lysis of the intraventricular clot, permits permeability of the drainage, and may reduce the incidence of chronic hydrocephaly requiring a permanent ventricular shunt.
Prat-Acín
R
R
Servicio de Neurocirugía, Hospital Universitario de Canarias, Sta. Cruz de Tenerife, España. ricprat@comtf.es
Galeano-Senabre
I
I
Conde-García
F J
FJ
Febles-García
P
P
González-Feria
L
L
D000328:Adult; D002543:Cerebral Hemorrhage / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002552:Cerebral Ventricles; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D006849:Hydrocephalus / Q000150:complications; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D014568:Urokinase-Type Plasminogen Activator